+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 16Years - 80Years
All Genders
ID06819891

Evaluating Afimkibart Induction Therapy for Moderately to Severely Active Crohns Disease A Double-Blind, Placebo-Controlled Phase III Study

Led by Hoffmann-La Roche · Updated on 2026-10-26

425

Participants Needed

208

Research Sites

225 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

CONDITIONS

Brief Title

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Research Team

R

Reference Study ID Number: GA45332 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here